Start the conversation
Leave a Reply
You must be logged in to post a comment.
I'm not afraid to make bold predictions.
That's particularly true when it comes to placing a target price on a fast-moving tech stock.
You folks know all about my prediction that Apple Inc. (Nasdaq: AAPL) will reach a split-adjusted price of $1,000 a share by Labor Day 2016.
Turns out, the stock is ahead of my projections. As of Feb. 27, AAPL is at $130, just 9.9% from hitting that milestone ($142.85 post-split), with 19 months until my target date.
I bring this up to make sure you all know that when I make my next big call I have the track record to back it up.
And I'm going to make that call right now - it's one that will double your money by 2018.
Let's get started...
The Social Network
So let's talk about why I predict that Facebook Inc. (Nasdaq: FB) will double to $161.36 a share in the next three years.
But before we do that, let's talk about why Wall Street just doesn't seem to understand the incredible value the stock represents.
I think the reason is simple. Many on the Street just don't trust Facebook because they still think of it as a social networking site for young people.
As the saying goes, "That was then, this is now." Facebook has moved well beyond its early days as a site just for teens and young adults to friend each other online.
Facebook is now, indisputably, the world leader in the social networking market, one that forecasters IBISWorld estimates at $9 billion. The research firm says that between 2009 and last year the industry grew by 36% a year.
And within that rapidly growing social networking market, Facebook is a business that meets the mandate of Rule No. 5 of my Tech Wealth Secrets - "Target stocks that can double your money."
Here Are 10 “One-Click” Ways to Earn 10% or Better on Your Money Every Quarter
Appreciation is great, but it’s possible to get even more out of the shares you own. A lot more: you can easily beat inflation and collect regular income to spare. There are no complicated trades to put on, no high-level options clearances necessary. In fact, you can do this with a couple of mouse clicks – passive income redefined. Click here for the report…
About the Author
Michael A. Robinson is a 36-year Silicon Valley veteran and one of the top tech and biotech financial analysts working today. That's because, as a consultant, senior adviser, and board member for Silicon Valley venture capital firms, Michael enjoys privileged access to pioneering CEOs, scientists, and high-profile players. And he brings this entire world of Silicon Valley "insiders" right to you...
- He was one of five people involved in early meetings for the $160 billion "cloud" computing phenomenon.
- He was there as Lee Iacocca and Roger Smith, the CEOs of Chrysler and GM, led the robotics revolution that saved the U.S. automotive industry.
- As cyber-security was becoming a focus of national security, Michael was with Dave DeWalt, the CEO of McAfee, right before Intel acquired his company for $7.8 billion.
This all means the entire world is constantly seeking Michael's insight.
In addition to being a regular guest and panelist on CNBC and Fox Business, he is also a Pulitzer Prize-nominated writer and reporter. His first book Overdrawn: The Bailout of American Savings warned people about the coming financial collapse - years before the word "bailout" became a household word.
Silicon Valley defense publications vie for his analysis. He's worked for Defense Media Network and Signal Magazine, as well as The New York Times, American Enterprise, and The Wall Street Journal.
And even with decades of experience, Michael believes there has never been a moment in time quite like this.
Right now, medical breakthroughs that once took years to develop are moving at a record speed. And that means we are going to see highly lucrative biotech investment opportunities come in fast and furious.
To help you navigate the historic opportunity in biotech, Michael launched the Bio-Tech Profit Alliance.
His other publications include: Strategic Tech Investor, The Nova-X Report, Bio-Technology Profit Alliance and Nexus-9 Network.